Three Versus Six Months of Adjuvant Oxaliplatin-Containing Chemotherapy for Patients With Stage III Colorectal Cancer: A Contemporary Real-World Analysis
In this contemporary cohort, 6 months chemotherapy is still being offered to patients with low-risk disease and is associated with more neuropathy. Exploration of patient preferences and resource costs may improve adoption of reduced duration adjuvant CAPOX in stage III CRC.
Authors
- Emily Leung (ORCID: https://orcid.org/0000-0001-6593-4865)
- Janine M. Davies (ORCID: https://orcid.org/0000-0003-3834-6835)
- Tharani Krishnan (ORCID: https://orcid.org/0000-0003-2566-7576)
- João Paulo Solar Vasconcelos (ORCID: https://orcid.org/0000-0002-7870-7765)
- Jonathan M. Loree (ORCID: https://orcid.org/0000-0001-8189-2132)
- Sharlene Gill (ORCID: https://orcid.org/0000-0003-3306-3617)
- Karamjit S. Gill
- Howard J. Lim (ORCID: https://orcid.org/0000-0002-5814-714X)
Institutions
- University of British Columbia (CA)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2024-10-09
- DOI
- https://doi.org/10.1200/op-24-00492
- Citations
- 3
- Primary Topic
- Colorectal Cancer Surgical Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.85